The samples include matched CD45+ peripheral blood leukocytes (PBL) as control samples and tumor-infiltrating leukocyte (TIL) samples, as well as CD45− non-immune cells obtained from primary tumors of 15 HNSCC patients. This evidence concerns the gene PTPRC and neoplasm.